RTx-303
RTx-303 is an orally active, selective DNA polymerase θ (Polθ) inhibitor (IC50 = 5.1 nM). RTx-303 exhibits significantly high cellular potency and strongly potentiates PARPi in BRCA1/2 mutant cells and patient-derived xenograft models. RTx-303 can be used for the study of BRCA2-mutated breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3035072-99-9
- Formule: C24H22D3F7N4O4
- Masse moléculaire:569.49
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
|
DNA Polymerase |
RTx-303 significantly inhibits Polθ-pol activity, but has no significant effect on other DNA polymerases (such as Polβ, Polη, Polγ, etc)[1].
RTx-303 (10 μM) shows no significant inhibition of most kinases (% activity >90%), and only mild inhibition of a few kinases, such as PASK (75% activity) and ATR/ATRIP (77% activity)[1].
RTx-303 shows an IC50 of 81.2 nM against HRD cells (HCT116 BRCA2-/-) and >1280 nM against HR-proficient cells (HCT116 BRCA2+/+), demonstrating >100-fold selectivity[1].
RTx-303 (5 μM, 5 days) in combination with Olaparib (HY-10162) significantly reduces the IC50 of ID8 BRCA2-/- cells (from 2 μM to 0.12 μM) and restores Olaparib sensitivity in PARPi-resistant cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | T1/2 | Cmax | AUClast | Tmax |
|---|---|---|---|---|---|---|
| Mice | 50 mg/kg | p.o. | 2.6 h | 2637 ng/mL | 30240 ng·h/mL | 3.3 h |
| Rat | 25 mg/kg | p.o. | 4.7 h | 1063 ng/mL | 12241 ng·h/mL | 3.3 h |
RTx-303 (60 mg/kg, p.o., twice daily for 56 days), in combination with Olaparib, can prevent acquired resistance to PARPi in BRCA1-mutant tumors in MDA-MB-436 xenograft mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:For the BR-05-0566 (BR-05-0568) BRCA2 mutant PDX study, ∼ 30 mm3 tumor fragment was implanted subcutaneously into female BALB/c mice 6-8 weeks old[1].
-
Dosage:60 mg/kg
-
Administration:P.o., twice daily for 28 days (BR-05-0566) to 42 days (BR-05-0568)
-
Result:BR-05-0566 model: Significantly inhibited tumor growth (compared to the vehicle group); combined with olaparib, it led to tumor regression; tumor volume reduction >80% in the combination group.
BR-05-0568 model: Combined with talazoparib, it resulted in 100% complete tumor elimination.
No significant weight loss was observed in any group.
-
Animal Model:10 × 106 MDA-MB-436 (bearing BRCA1-Mutant) cells were injected with Matrigel subcutaneously into female BALB/c mice, 6-8 weeks old[1].
-
Dosage:60 mg/kg
-
Administration:P.o., twice daily for 56 days
-
Result:Treated with Olaparib, tumors regressed rapidly and there was no recurrence.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 3035072-99-9
-
Unlabeled Cas 3035072-66-0
-
Masse moléculaire 569.49
-
Formule C24H22D3F7N4O4
-
SMILES
CN(C)C[C@@H](O)CN(C1=O)CCN1C2=C(OC(N(C([2H])([2H])[2H])C3=CC=C(F)C=C3)=O)C(C(F)(F)F)=CC(C(F)(F)F)=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
RTx-303 Related Classifications
HY-179219S Related Classifications
Powered by Bioz